Suspected Cancer: recognition and referralStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 March 2026
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC